Association between preoperative cholecalciferol therapy and hypocalcemia after parathyroidectomy in patients with primary hyperparathyroidism

BACKGROUND: Primary hyperparathyroidism (PHPT) is a endocrine disorder characterized by excessive secretion of parathyroid hormone (PTH) from parathyroid gland tumors. Parathyroidectomy (PTE) is the main treatment for PHPT, but it can lead to hypocalcemia in up to 46% of cases. Hypocalcemia is associated with seizures and life-threatening cardiac arrhythmias, and vitamin D deficiency can exacerbate PHPT severity and contribute to «hungry bones syndrome,» resulting in severe and persistent postoperative hypocalcemia.

AIM: To evaluate the association and determine the strength of the relationship between preoperative cholecalciferol therapy and the occurrence of hypocalcemia within 1–3 days after PTE in patients with PHPT.

MATERIALS AND METHODS: The study was conducted at the Endocrinology Research Centre, during the periods of 1993–2010 and 2017–2020. The inclusion criteria consisted of patients diagnosed with PHPT who required PTE, had a serum 25-hydroxyvitamin D (25(OH)D) level below 20 ng/mL, and a serum total calcium level below 3 mmol/L. The exclusion criterion was the use of medications that affect calcium-phosphorus metabolism, including cinacalcet, denosumab, or bisphosphonates, either as monotherapy or as part of combination therapy.

RESULTS: There were 117 patients, including 110 (94%) females and 7 (6%) males. The median age and interquartile range were 58 [49; 65] years. Among the participants, 21 (18%) received cholecalciferol supplementation for a duration of 2 weeks to 2 months prior to PTE, aiming to address vitamin D deficiency. The remaining 96 (82%) participants did not receive ­cholecalciferol supplementation. Both groups, i.e., participants receiving cholecalciferol and those who did not, were similar in terms of anthropometric factors (sex and age at the time of surgery), preoperative clinical characteristics (BMD decrease), and laboratory parameters (PTH, total calcium, phosphorus, ALP, OC, CTX-1, and 25(OH)D levels). The occurrence of postoperative hypocalcemia was significantly lower in participants who received cholecalciferol supplementation (10% vs. 63%, p<0,001, FET2). Cholecalciferol intake showed a negative association with hypocalcemia development (RR=0,15, 95% CI (0,03; 0,51)).

CONCLUSION: Preoperative cholecalciferol supplementation for 2 weeks to 2 months before PTE reduces the risk of postoperative hypocalcemia in patients with PHPT by 2–33 times.

1. Duan K, Gomez Hernandez K, Mete O. Clinicopathological correlates of hyperparathyroidism // J Clin Pathol. England, 2015. Vol. 68, №10. P. 771–787. doi: https://doi.org/10.1136/jclinpath-2015-203186

2. Первичный гиперпаратиреоз. Клинические рекомендации. [Electronic resource]. URL: http://cr.rosminzdrav.ru/schema/88_4

3. Eremkina A, et al. Denosumab for management of severe hypercalcemia in primary hyperparathyroidism // Endocr Connect. 2020. Vol. 9, №10. P. 1019–1027. doi: https://doi.org/10.1530/EC-20-0380

4. Walker MD, Bilezikian JP. Vitamin D and primary hyperparathyroidism: more insights into a complex relationship // Endocrine. United States, 2017. Vol. 55, №1. P. 3–5. doi: https://doi.org/10.1007/s12020-016-1169-1

5. Rao DS, et al. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism // J Clin Endocrinol Metab. United States, 2004. Vol. 89, №11. P. 5415–5422. doi: https://doi.org/10.1210/jc.2004-0028

6. Witteveen JE, et al. Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature // Eur J Endocrinol. England, 2013. Vol. 168, №3. P. R45–53. doi: https://doi.org/10.1530/EJE-12-0528

7. Acharya R. et al. Vitamin D repletion in primary hyperparathyroid patients undergoing parathyroidectomy leads to reduced symptomatic hypocalcaemia and reduced length of stay: a retrospective cohort study // Ann R Coll Surg Engl. England, 2022. Vol. 104, № 1. P. 41–47. doi: https://doi.org/0.1308/rcsann.2021.0078

8. Edafe O, et al. Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia // Br J Surg. England, 2014. Vol. 101, №4. P. 307–320. doi: https://doi.org/10.1002/bjs.9384

9. Erbil Y, et al. Determinants of postoperative hypocalcemia in vitamin D-deficient Graves’ patients after total thyroidectomy // Am J Surg. United States, 2011. Vol. 201, №5. P. 685–691. doi: https://doi.org/10.1016/j.amjsurg.2010.04.030

10. Lorente-Poch L. et al. Defining the syndromes of parathyroid failure after total thyroidectomy // Gland Surg. China (Republic: 1949- ), 2015. Vol. 4, № 1. P. 82–90. doi: https://doi.org/10.3978/j.issn.2227-684X.2014.12.04

11. Bilezikian JP, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research // J Bone Miner Res. United States, 2011. Vol. 26, № 10. P. 2317–2337. doi: https://doi.org/10.1002/jbmr.483

12. Jakubauskas M, Beiša V, Strupas K. Risk factors of developing the hungry bone syndrome after parathyroidectomy for primary hyperparathyroidism // Acta Med Litu. 2018. Vol. 25, № 1. P. 45–51. doi: https://doi.org/10.6001/actamedica.v25i1.3703

13. Kidwai SM, et al. Risk stratification for outpatient parathyroidectomy and predictors of postoperative complications // Am J Otolaryngol. United States, 2017. Vol. 38, № 1. P. 26–30. doi: https://doi.org/10.1016/j.amjoto.2016.09.006

14. Pludowski P. et al. Vitamin D supplementation guidelines // J Steroid Biochem Mol Biol. England, 2018. Vol. 175. P. 125–135. doi: https://doi.org/10.1016/j.jsbmb.2017.01.021

15. Malabu UH, Founda MA. Primary hyperparathyroidism in Saudi Arabia: a review of 46 cases // Med J Malaysia. Malaysia, 2007. Vol. 62, № 5. P. 394–397. PMID: 18705474

16. Fong J, Khan A. Hypocalcemia: updates in diagnosis and management for primary care // Can Fam Physician. Canada, 2012. Vol. 58, № 2. P. 158–162. PMID: 22439169

17. Остеопороз. Клинические рекомендации. [Electronic resource]. URL: https://cr.minzdrav.gov.ru/schema/87_4

18. Nelson HD, et al. Screening for Osteoporosis: Systematic Review to Update the 2002 US Preventive Services Task Force Recommendation. Rockville (MD): Agency for Healthcare Research and Quality (US). Rockville (MD), 2010. PMID: 20722176

19. Bonnick S. Bone Densitometry in Clinical Practice. 2004. 411 p.

20. WHO Scientific Group Technical Report. Assessment of osteoporosis at the primary health-care level. Technical Report. [Electronic resource]. 2007. URL: https://frax.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf.

21. Salman MA, et al. Role of vitamin D supplements in prevention of hungry bone syndrome after successful parathyroidectomy for primary hyperparathyroidism: A prospective study // Scand J Surg. England, 2021. Vol. 110, № 3. P. 329–334. doi: https://doi.org/10.1177/1457496920962601

22. UnsaI LO, et al. Preoperative Vitamin D Levels as a Predictor of Transient Hypocalcemia and Hypoparathyroidism After Parathyroidectomy // Sci Rep. 2020. Vol. 10, № 1. P. 9895. doi: https://doi.org/10.1038/s41598-020-66889-8

23. Press D. et al. The effect of vitamin D levels on postoperative calcium requirements, symptomatic hypocalcemia, and parathormone levels following parathyroidectomy for primary hyperparathyroidism // Surgery. United States, 2011. Vol. 150, № 6. P. 1061–1068. doi: https://doi.org/10.1016/j.surg.2011.09.018

24. Rolighed L. et al. Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial // J Clin Endocrinol Metab. United States, 2014. Vol. 99, № 3. P. 1072–1080. doi: https://doi.org/10.1210/jc.2013-3978